Princeton Global Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Princeton Global Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-83	Closed	-$9K	–	570
2022 Q3	$9K	Hold	83	–	–	﹤0.01%	399
2022 Q2	$8K	Hold	83	–	–	﹤0.01%	426
2022 Q1	$8K	Hold	83	–	–	﹤0.01%	471
2021 Q4	$7K	Hold	83	–	–	﹤0.01%	436
2021 Q3	$8K	Hold	83	–	–	﹤0.01%	422
2021 Q2	$8K	Hold	83	–	–	﹤0.01%	431
2021 Q1	$8K	Hold	83	–	–	﹤0.01%	401
2020 Q4	$8K	Hold	83	–	–	﹤0.01%	403
2020 Q3	$8K	Hold	83	–	–	﹤0.01%	359
2020 Q2	$10K	Hold	83	–	–	﹤0.01%	418
2020 Q1	$7K	Hold	83	–	–	﹤0.01%	411
2019 Q4	$9	Hold	83	–	–	﹤0.01%	442
2019 Q3	$8K	Sell	83 -14	-14%	-$1.31K	﹤0.01%	303
2019 Q2	$8K	Buy	+97	New	+$7.96K	﹤0.01%	337

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Princeton Global Asset Management's NBIX Position: Q4 2022 in Review

Princeton Global Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 83 shares — an estimated $9K sold.

Princeton Global Asset Management first reported a position in NBIX in Q2 2019 and held it in 14 quarters. The position peaked at $10K in Q2 2020. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

Princeton Global Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
Princeton Global Asset Management sold 83 Neurocrine Biosciences shares in Q4 2022, an estimated $9K.
Princeton Global Asset Management first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 14 quarters.
Princeton Global Asset Management's Neurocrine Biosciences position peaked at $10K in Q2 2020.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Princeton Global Asset Management's 13F filing for Q4 2022, filed 6 Feb 2023.